Overview

New Formulations of Propafenone to Treat Atrial Fibrillation

Status:
Terminated

Trial end date:
2020-04-01

Target enrollment:

Participant gender:

Summary

Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Vanderbilt University

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Propafenone